Literature DB >> 15858400

Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study.

Michael Ganz1, Rasoul Mokabberi, Domenic A Sica.   

Abstract

An open-label drug substitution study showed that controlled-release isradipine (Dynacirc-CR) can be safely substituted for amlodipine on a mg-for-mg basis in patients with mild-to-moderate hypertension. When controlled-release isradipine was substituted for amlodipine, blood pressure was more effectively controlled, and edema rates were reduced. When subjects resumed amlodipine therapy, the previous gain in blood pressure reduction and lessening of edema vanished. The basis for this more favorable pattern of efficacy and side-effects with controlled-release isradipine, although mechanistically unresolved, may relate to a lesser degree of sympathetic nervous system activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858400      PMCID: PMC8109349          DOI: 10.1111/j.1524-6175.2005.04450.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  19 in total

1.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

2.  Emerging data on calcium-channel blockers: the COHORT study.

Authors:  Alberto Zanchetti
Journal:  Clin Cardiol       Date:  2003-02       Impact factor: 2.882

3.  At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study.

Authors:  L Hermans; A Deblander; P De Keyser; I Scheys; E Lesaffre; K J Westelinck
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

4.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

5.  Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine.

Authors:  Per Lund-Johansen; Einar Stranden; Steiner Helberg; Terje Wessel-Aas; Knut Risberg; Per K Rønnevik; Helge Istad; Sverre Madsbu
Journal:  J Hypertens       Date:  2003-05       Impact factor: 4.844

6.  A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group.

Authors:  S A Cutler; J J Hammond
Journal:  Am J Hypertens       Date:  1993-03       Impact factor: 2.689

Review 7.  Calcium channel antagonists in the treatment of hypertension.

Authors:  Michael A Weber
Journal:  Am J Cardiovasc Drugs       Date:  2002       Impact factor: 3.571

8.  Comparative evaluation of the antihypertensive efficacy of once-daily sustained-release isradipine and lacidipine using 24-hour ambulatory blood-pressure monitoring.

Authors:  M Galderisi; A Petrocelli; M Garofalo; A Celentano; A Alfieri; O de Divitiis
Journal:  J Int Med Res       Date:  1995 Jul-Aug       Impact factor: 1.671

9.  Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects.

Authors:  Fabio Angeli; Paolo Verdecchia; Gian Paolo Reboldi; Roberto Gattobigio; Maurizio Bentivoglio; Jan A Staessen; Carlo Porcellati
Journal:  Am J Hypertens       Date:  2004-09       Impact factor: 2.689

10.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

View more
  1 in total

1.  The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

Authors:  E Ilijic; J N Guzman; D J Surmeier
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.